Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Gil Melmed MD, MS, AGAF

Gil Y. Melmed MD, MS, AGAF

Co-Director, Inflammatory Bowel Disease Center; Director, Clinical Research, Inflammatory Bowel and Immunobiology Research Institute, Division of Digestive and Liver Diseases, Department of Medicine; Professor of Medicine, Cedars-Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California

Gil Y. Melmed, MD, MS, is the Co-Director of the Inflammatory Bowel Disease Center and Professor of Medicine at Cedars-Sinai Medical Center in Los Angeles, California. His research and educational interests span clinical and surgical outcomes, quality of care, and preventive health issues in IBD. He has authored or coauthored more than 200 articles in peer-reviewed journals and several book chapters. He has led or participated in the development of quality indicators for IBD with the American Gastroenterology Association, the Crohn’s and Colitis Foundation, the National Quality Forum, and the Canadian Crohn’s and Colitis organizations


Dr. Melmed reports the following: 
  • Consultant: AbbVie, Arena, Bristol-Myers Squibb, Boehringer-Ingelheim, Ferring, Janssen, Medtronic, Nephroceuticals, Oshi, Pfizer, Samsung Bioepis, Shield, Shionogi, Takeda
  • Research funding: Pfizer

Recent Contributions to PracticeUpdate:

  1. Recurrent Crohn's Disease After Ileocolonic Resection